EDITORIAL

In a recent publication “Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma” (Nature 2014)[1], the authors concluded that their “findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a ‘drug holiday’ and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.”